TNF‐related apoptosis‐inducing ligand as a therapeutic agent in autoimmunity and cancer
- 1 February 2006
- journal article
- review article
- Published by Wiley in Immunology & Cell Biology
- Vol. 84 (1) , 87-98
- https://doi.org/10.1111/j.1440-1711.2005.01413.x
Abstract
Recombinant, soluble TNF‐related apoptosis‐inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and 2 clinical trials using agonistic mAbs that engage the human TRAIL receptors DR4 and DR5 have also provided encouraging results. It is now evident that TRAIL suppresses autoimmune disease in various experimental animal models, suggesting that the therapeutic value of recombinant TRAIL and agonistic DR4 and DR5 mAbs might also extend to the suppression of autoimmune disease. This review provides an insight into our current understanding of the role(s) of TRAIL in disease, with a specific focus on cancer and autoimmunity. We also emphasize biological agents and drugs that sensitize tumour cells to TRAIL‐mediated apoptosis and discuss the potential molecular basis for their sensitization.Keywords
Funding Information
- National Institutes of Health (NO1‐CO‐12400)
- National Institutes of Health
- National Cancer Institute
This publication has 124 references indexed in Scilit:
- Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell deathBritish Journal of Haematology, 2005
- Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma CellsCancer Research, 2005
- Association of death receptor 4 haplotype 626C–683C with an increased breast cancer riskCarcinogenesis: Integrative Cancer Research, 2005
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 2004
- Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2004
- Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanismsThe Prostate, 2004
- Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cellsOncogene, 2003
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 2003